Publications

Abstract

Background: Clinical data suggest that females might be more resistant to hypoxia than males, with male sex recognized as a risk factor for suffering life-long neurological sequelae. However, the impact of hypoxia-ischemia in certain brain regions and its association with genetic sex remains unclear.

Methods: Using the piglet model of neonatal brain injury, fifteen piglets (8 females and 7 males) were subjected to a global cerebral hypoxic-ischemic insult. After 48 h, total cell death and the number of necrotic, apoptotic and cleaved-caspase-3 positive cells was quantified in five brain regions.

Results: Male piglets exposed to hypoxia-ischemia were more vulnerable than females (total cell death p < 0.01), also showing a region-specific response to brain injury depending on sex, with males being more affected in both deep gray (caudate p < 0.01; THAL p < 0.0001) and white (p < 0.01) matter. Despite necrosis was the primary form of cell death for both sexes, the pattern of cell death differed: while male piglets showed more necrosis (p < 0.0001), apoptosis (p < 0.0001) and caspase-3 activation (p < 0.0001) were higher in females.

Conclusion: Our results suggest that male piglets were globally and regionally more vulnerable than females after HI; further, both the pattern of cell death and the apoptotic molecular mechanisms were sexually dimorphic.

Impact: Clinical data suggest that females might be more resistant to perinatal asphyxia than male newborns. The impact of hypoxia-ischemia in certain brain regions and the association of cell death patterns with sex remain unclear. Hypoxic-ischemic male piglets were more vulnerable than females, showing also increased regional vulnerability in both deep gray and white matter areas. Although necrosis was the primary form of cell death for both sexes, male piglets showed more necrosis, whereas apoptosis and caspase-3 activation were higher in females. Neonatal brain injury and therapeutic responses may be sex-dependent due to differences in cell death patterns and molecular mechanisms.

Abstract

Chronic histiocytic intervillositis (CHI) is an inflammatory condition of the placenta, characterised by an abnormal, mainly macrophagic infiltrate within the intervillous space. Recent research suggests that CHI results from a ‘maternal‐foetal rejection’ mechanism, because at least some CHI cases fulfil the criteria for antibody‐mediated rejection (AMR) of kidney allografts according to the Banff classification [i.e. presence of anti‐human leukocyte antigen (HLA) paternal antibodies activating the complement or foetal‐specific antibodies (FSA), a macrophage‐rich infiltrate, and positive C4d immunostaining]. To gain further insights into CHI pathogenesis, we aimed to refine the phenotype of the inflammatory infiltrate using a multiplex immunofluorescence technique and to compare the mRNA signatures between CHI and AMR of kidney allografts. Twelve patients with C4d+ FSA+ CHI were included in the study and compared to a control group of 5 patients without inflammatory lesions on placental examination. We developed a multiplex immunofluorescence panel to identify CD4+ and CD8+ T lymphocytes, CD68+/CD206− and CD68+/CD206+ macrophages, and NK cells in the villi and intervillous space. Molecular signatures were studied using NanoString® technology and the B‐HOT panel recommended by the Banff classification for kidney allografts. Multiplex immunofluorescence revealed that the infiltrate in the intervillous space was mainly composed of CD68+/CD206− macrophages as well as a higher proportion of CD8+ lymphocytes in patients with CHI compared to controls. Densities of NK cells and CD4 T cells were very low. Molecular signatures showed an overexpression of HLA class II genes, an IFN‐γ signature, and cytokine gene sets in C4d+ FSA+ CHI patients, also involved in kidney AMR. These results reinforce the paradigm of maternal‐foetal rejection.

Abstract

Background: Before 26 weeks of gestational age, because extremely preterm infants (EPI) face a high risk of death or disability, management decisions may involve either active treatment or palliative care. Survival chances largely depend on the willingness of medical teams and parents to opt for active management. Variability of practices explains differences in survival between countries and regions, and interpersonal variability may also exist among caregivers within the same center. Our objective was to study the variability of management decisions and their determinants among caregivers in a French type 3 maternity hospital.

Methods: All caregivers, obstetricians, pediatricians, and midwives, involved in the management of EPI in a type 3 perinatal center were surveyed using a self-administered questionnaire. Each respondent reported their personal thresholds for deciding on active management, defined as the unborn child’s estimated likelihood of survival without severe neonatal morbidity. Median and interquartile ranges (IQR) of these thresholds were calculated and compared by respondent characteristics.

Results: 85 (75%) eligible professionals responded. The median threshold of survival without severe neonatal morbidity below which active management was deemed impossible was 15% (IQR 10-30%), while the median threshold above which active management could not be refused was 80% (IQR 70-90%). Wide IQRs indicated significant variability in individual thresholds. This variability appeared to be influenced by profession and gender but was not associated with factors such as having children, age, experience, or the personal estimates of the neonates’ outcomes.

Conclusions: Decision thresholds for active management of EPI, expressed in terms of survival without severe neonatal morbidity, vary significantly among professionals. The thresholds reported in our study were notably higher than those observed in other countries, which may help explain the lower rates of active management before 26 weeks in France. Recognizing these differences and comparing personal thresholds with peers could facilitate more consensus-based decision-making within teams.

Abstract

BACKGROUND: The objective of this study was to evaluate total circulating PlGF (placental growth factor) and free PlGF concentrations to provide insights into the mechanisms of decreased PlGF noted in preeclampsia and fetal growth restriction.

METHODS: We conducted a retrospective single-center study in pregnant women receiving care for suspected preeclampsia or fetal growth restriction. Serum angiogenic proteins (sFLT1 [soluble fms-like tyrosine kinase] and free PlGF) were measured on an automated platform as part of standard-of-care. Total PlGF concentrations in the serum were directly measured using a validated biochemical procedure that dissociated circulating sFLT1 and PlGF complexes. Small for gestational age (SGA) was defined by birthweight ≤10th percentile.

RESULTS: Of the 407 women studied, 155 women did not develop preeclampsia or SGA (control group), 111 women developed SGA without preeclampsia (SGA group), 71 women developed preeclampsia without SGA (preeclampsia group), and 70 developed preeclampsia and SGA (preeclampsia+SGA group). Despite reductions in free PlGF levels (229 [158–321] pg/mL), total PlGF levels were not reduced in the preeclampsia group (1020 [738–1444] pg/mL) compared with the control group (1077 [763–1595] pg/mL). In contrast, the total PlGF levels were significantly reduced in the SGA group (744 [462–1161] pg/mL; P<0.0001) and the preeclampsia +SGA group (616 [349–917] pg/mL; P<0.0001) compared with the control group (1077 [763–1595] pg/mL).

CONCLUSIONS: Placental dysfunction associated with preeclampsia, characterized by reduced free PlGF levels but unchanged total PlGF, is driven by excessive placental production of sFLT1. Placental dysfunction associated with SGA, marked by reductions in both free and total PlGF, is mediated by decreased placental PlGF production.

Abstract

Background

This study aimed to investigate the health-related quality of life (HRQoL) at 5 years of age of European children born very preterm across multi-dimensional outcomes by presence and severity of congenital anomalies.

Methods

The study used data from a European cohort of children born very preterm (<32 weeks of gestation) and followed up to 5 years of age (N = 3493). Multilevel Ordinary Least Squares (OLS) regression were used to explore the associations between the presence and severity of congenital anomalies.

Results

The mean total PedsQL™ GCS score for children with a mild congenital anomaly was lower than the respective value for children without a congenital anomaly by 3.7 points (p < 0.05), controlling for socioeconomic variables only; this effect was attenuated when accumulatively adjusting for perinatal characteristics (3.3 points (p < 0.05)) and neonatal morbidities (3.1 (p < 0.05)). The mean total PedsQL™ GCS scores for children who had a severe congenital anomaly were lower by 7.1 points (p < 0.001), 6.6 points (p < 0.001) and 6.0 points (p < 0.001) when accumulatively adjusting for socioeconomic, perinatal and neonatal variables, respectively.

Conclusion

This study revealed that the presence and severity of congenital anomalies are significant predictors of HRQoL outcomes in children born very preterm

Abstract

This nationwide cohort study provides a comprehensive overview of maternal and perinatal outcomes associated with sickle cell disease (SCD) during pregnancy. Using the French national health database, all singleton pregnancy-related hospital discharges from 2013 to 2020 in women aged 15–55 (n = 5 752 080) were selected. Of these, 1022 births were to women with SCD, 308 of whom were on long-term treatment, that is, hydroxyurea (HU) and/or transfusion programme. Pregnancies with SCD were more likely to involve pre-eclampsia (9.6% vs. 1.7%; p < 0.001), pulmonary embolism (0.70% vs. 0.02%; p < 0.001), caesarean sections (52.8% vs. 18.2%; p < 0.001) and postpartum haemorrhage (8.3% vs. 4.1%; p < 0.001) compared to pregnancies without SCD. Preterm birth (<37 weeks) was much more common in women with SCD (28.5% vs. 5.6%). Infants born to women with SCD faced greater adverse neonatal outcomes (22.4% vs. 8.0%; p < 0.001). Although untreated SCD was linked to fewer complications than long-term treated SCD, both conditions presented greater risks compared with pregnancies without SCD. Unexpectedly, babies born to women with SCD had a higher incidence of congenital abnormalities (6.3% vs. 3.4%; p < 0.001), not attributed to HU use. Overall, despite advances in SCD management, pregnancy in SCD remains a high-risk condition, for both mothers and babies.

Abstract

Introduction: the literature extensively documents neonatal and paediatric outcomes related to preterm delivery,
but maternal health in this circumtances remains underexplored.
This study aimed to identify women with antepartum severe maternal morbidity (SMM) among those delivering
preterm and explore whether they delivered in hospitals with risk-appropriate maternal care facilities.
Material and methods: Women giving birth at 22–34 weeks of gestation were identified from the French national
prospective EPIPAGE-2 cohort study in 2011; terminations of pregnancy for fetal congenital malformations were
excluded. Antepartum SMM was defined as a composite outcome of severe maternal morbid events preceding
labour onset or the delivery decision. We described antepartum SMM and compared women with and without
SMM regarding the characteristics of the hospital of delivery.
Results : among 5,690 women included, 886 (16.0 %, 95 % CI, 14.7, 17.0) experienced antepartum SMM, pri-
marily due to severe pregnancy-related hypertensive disorders or major obstetric bleeding. Women with ante-
partum SMM were more likely to deliver in level III maternity units (level of neonatal care) compared with
women without antepartum SMM (68.0 % vs 59.3 %, P < 0.001). However, 18.3 % of women with antepartum
SMM delivered in hospitals without an onsite adult critical care unit, a proportion not significantly different from
those without SMM (22.0 %, P = 0.23).
Conclusions : antepartum SMM affected one in six women delivering at 22–34 weeks’ gestation. Many did not
deliver in hospitals equipped with adult critical care unit. Delivery locations for women with SMM at risk of
preterm birth should address the needs of both the mother and the newborn.

Abstract

Introduction: The literature extensively documents neonatal and paediatric outcomes related to preterm delivery, but maternal health in this circumtances remains underexplored. This study aimed to identify women with antepartum severe maternal morbidity (SMM) among those delivering preterm and explore whether they delivered in hospitals with risk-appropriate maternal care facilities.

Material and methods: Women giving birth at 22-34 weeks of gestation were identified from the French national prospective EPIPAGE-2 cohort study in 2011; terminations of pregnancy for fetal congenital malformations were excluded. Antepartum SMM was defined as a composite outcome of severe maternal morbid events preceding labour onset or the delivery decision. We described antepartum SMM and compared women with and without SMM regarding the characteristics of the hospital of delivery.

Results: Among 5,690 women included, 886 (16.0 %, 95 % CI, 14.7, 17.0) experienced antepartum SMM, primarily due to severe pregnancy-related hypertensive disorders or major obstetric bleeding. Women with antepartum SMM were more likely to deliver in level III maternity units (level of neonatal care) compared with women without antepartum SMM (68.0 % vs 59.3 %, P < 0.001). However, 18.3 % of women with antepartum SMM delivered in hospitals without an onsite adult critical care unit, a proportion not significantly different from those without SMM (22.0 %, P = 0.23).

Conclusions: Antepartum SMM affected one in six women delivering at 22-34 weeks’ gestation. Many did not deliver in hospitals equipped with adult critical care unit. Delivery locations for women with SMM at risk of preterm birth should address the needs of both the mother and the newborn.

Abstract

Objective: to determine whether pulmonary hypertension (PH) is associated with higher risk of adverse neuro-
developmental outcome at age 5 in a population-based cohort of 22–31+6 preterm children.
Study design : in the EPIPAGE-2 French prospective population-based cohort of preterm children born in 2011, the neurodevelopmental outcome of children with PH was collected at 5 years. The primary outcome was a com-
posite measure with four levels of neurodevelopmental disabilities: severe, moderate, mild, no disability, based
on cerebral palsy, visual, hearing or cognitive deficiencies, behavioral difficulties and developmental coordi-
nation disorders. Secondary outcomes were autism spectrum disorders and school attendance. Missing data were multiply imputed. Developmental measures were compared using generalized estimating equations models.
Results : Of the 3007 eligible children, 1825 were analyzed, of whom 79 (4.3 %) were PH+. At age 5, 36.9 % (95
% CI, 26.0–47.8) of PH + children had moderate to severe overall neurodevelopmental disabilities compared
with 17.9 % (95 % CI, 16.1–19.8) of PH–children, P < 0.001. Significant differences at 5 years between the PH+
and PH– groups were observed for cerebral palsy (CP) (6 % versus 2.3 % for severe CP, P = 0.003), cognitive
deficiency (31.7 % versus 15.0 %, P < 0.001) and developmental coordination disorders (27.1 % versus 11.7 %,
P < 0.001). There were no significant differences in behavioral difficulties and autism spectrum disorders.
Normal school was attended by 69.2 % of PH + children versus 88.3 % of PH– children.
Conclusion : In this nationwide population-based cohort of extremely preterm and very preterm infants, moderate to severe overall neurodevelopmental disability at age 5 was significantly associated with neonatal PH.

Abstract

Background and objectives: Genetic primary microcephaly (PM) is a defect in early brain development leading to congenital microcephaly, mostly recessively inherited, and mild-to-moderate intellectual disability. PM has been largely elucidated, thanks to exome and genome sequencing. However, radial microbrain, the most severe form of genetic PM or micrencephaly described in the 1980s, which leads to early lethality or very severe intellectual handicap, remains without a molecular diagnosis. We sought to identify the cause of radial microbrain by analyzing the genotype of children/adults and fetuses with an extremely small brain.

Methods: We searched for individuals with the smallest head circumference among patients with a confirmed diagnosis of PM included in 2 French and European observational studies coordinated at the Robert Debré Children’s Hospital in Paris. Their neurodevelopment and brain imaging were analyzed, as well as next-generation sequencing for a panel of microcephaly genes or exome sequencing. Neuropathologic and immunohistologic analyses of extremely severe microcephalic fetal brains and stage-matched controls were performed. A nonparametric test and Mann-Whitney post-test were used to compare the cortical thickness between groups.

Results: We identified 5 individuals (4 female patients, 7 years 10 months-19 years) with a particularly small brain among a series of 50, all suffering from a severe neurodevelopmental disorder with no ability to communicate verbally and, in 3 of them, no ability to walk. Genetic analysis revealed in all individuals the presence of the same homozygous variant c.2953A>G (p.R985G) in the RTTN gene (ROTATIN). The same variant was found in 2 fetuses whose neuropathologic evaluation showed a major reduction in the thickness of the ventricular zone and neuronal heterotopias. The cortical plate was reduced by 70% compared with controls, irrespective of the region considered. Immunostaining with vimentin showed a 50% loss of radial glial columns, characteristic of radial microbrain.

Discussion: Our data show that the homozygous c.2953A>G substitution in RTTN is a recurrent variant responsible for radial microbrain, the most severe form of primary microcephaly. Our combined neurologic, imaging, and histopathologic approaches provide a better understanding of the severity of this condition and its prognosis.

Trial registration information: ClinicalTrials.gov number: NCT01565005.